The U.S. central nervous system (CNS) therapeutics market, valued at USD 43.12 billion in 2024 and forecast to grow at a CAGR of 7.0% between 2025 and 2034, reflects a highly segmented ecosystem driven by innovation across treatment classes, therapeutic indications, and patient demographics. Segment-wise performance in the market is increasingly dictated by tailored product differentiation, the...